Daxor says HFSA study shows blood volume analysis improves diuresis in mechanical pump heart failure patients

Bitget2026/10/14 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Daxor reported new clinical study results already presented at HFSA 2026, alongside signs of rising clinician interest in its BVA diagnostic system.
Data in high-acuity heart failure patients suggested direct blood-volume measurement can reveal missed fluid and anemia issues, supporting more targeted treatment decisions.
A separate advanced heart failure analysis indicated BVA can identify a previously hard-to-detect volume condition, positioning the tool as a differentiator in care pathways.
The update strengthens Daxor’s commercial pitch that improved diagnostic precision could reduce misdiagnosis risk, supporting adoption discussions with hospital clinicians.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daxor Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140800PRIMZONEFULLFEED9845572) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Daxor says HFSA study shows blood volume analysis improves diuresis in mechanical pump heart failure patients

You may also like

Crypto prices